The effectiveness of another neuroprotective drug, raloxifene (a selective estrogen receptor modulator) as adjunctive therapy to antipsychotics in patients with schizophrenia or schizoaffective disorder was also examined in clinical trials [42,43,44,45,46]. Here, ESR1 is linked to schizophrenia.